Herbs (Global Traditional) · European
Coltsfoot (Tussilago farfara) (Tussilago farfara)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Coltsfoot (Tussilago farfara) is a European herb containing pyrrolizidine alkaloids and flavonoids that exhibits anti-inflammatory activity by inhibiting arachidonic acid metabolism. The plant's phenolic compounds demonstrate antimicrobial effects against gram-negative bacteria in laboratory studies.
Coltsfoot (Tussilago farfara) is a perennial herb native to Europe and Asia that spreads from a branched rhizome. The plant's leaves and flower buds are traditionally harvested and used medicinally, typically prepared as leaf extracts, decoctions, or standardized herbal preparations.
The available research on coltsfoot lacks human clinical trials, randomized controlled trials, or meta-analyses. Current evidence is limited to in vitro pharmacological studies and phytochemical composition analyses, with no PubMed PMIDs provided for clinical efficacy data.
No clinically studied dosage ranges are available in the research. The sources document phytochemical composition but do not include human dosage studies or standardization protocols. Consult a healthcare provider before starting any new supplement.
Coltsfoot (Tussilago farfara) is used primarily as a medicinal herb rather than a food source, so comprehensive macronutrient data per 100g of fresh or dried leaf is limited in standard nutritional databases. Key bioactive compounds and phytochemical constituents include: **Mucilage polysaccharides** (~6–10% of dry weight in leaves), composed primarily of arabinose, galactose, glucose, and uronic acid units, which contribute to its traditional demulcent properties. **Flavonoids** include rutin (~0.3–0.7% dry weight), quercetin, kaempferol, hyperoside, isoquercetin, apigenin, and luteolin; apigenin and luteolin are present at lower concentrations (~0.01–0.05% dry weight) but are notable for their documented anti-proliferative activity. **Phenolic acids** include caffeic acid, ferulic acid, chlorogenic acid (~0.1–0.5% dry weight), and 3,5-dicaffeoylquinic acid, which contribute to antioxidant and antimicrobial activity. **Tussilagone** (a sesquiterpene) is a signature bioactive compound found at approximately 0.1–0.3% of dry flower weight, with documented anti-inflammatory and cardiovascular-relaxant activity. **Pyrrolizidine alkaloids (PAs)**, notably senkirkine (~0.005–0.015% dry weight) and senecionine (trace amounts), are hepatotoxic and potentially genotoxic — this is a critical safety concern limiting internal use. **Tannins** are present at approximately 5–8% dry weight, contributing astringent properties. **Minerals**: leaves contain potassium (~15–25 mg/g dry weight), calcium (~10–20 mg/g), magnesium (~2–5 mg/g), iron (~0.1–0.5 mg/g), and zinc (trace). **Vitamin C** is present in modest amounts in fresh leaves (~10–30 mg/100g fresh weight, estimated). **Sterols** include β-sitosterol and faradiol. **Fiber** content of dried leaves is relatively high (~15–25% crude fiber). Protein content of dried leaves is approximately 6–10%. **Bioavailability notes**: Mucilage polysaccharides are not significantly absorbed but exert local soothing effects on mucosal surfaces. Flavonoid glycosides (rutin, hyperoside) require intestinal hydrolysis for aglycone absorption, resulting in moderate bioavailability (~5–20%). Tussilagone is lipophilic and reasonably well absorbed orally. Pyrrolizidine alkaloids are readily absorbed and hepatically bioactivated to toxic pyrrolic metabolites, underscoring the toxicological concern even at low dietary exposure levels.
Coltsfoot's anti-inflammatory effects occur through inhibition of arachidonic acid metabolism and suppression of nitric oxide production in activated macrophages. The plant's phenolic compounds, including flavonoids like rutin and quercetin, disrupt bacterial cell wall integrity in gram-negative bacteria such as E. coli. However, pyrrolizidine alkaloids present in coltsfoot can cause hepatotoxicity through metabolic conversion to reactive pyrrole derivatives.
Current evidence for coltsfoot is limited to in vitro studies demonstrating anti-inflammatory and antimicrobial activities. Laboratory studies show leaf extracts inhibit inflammatory mediators in macrophage cell lines and exhibit bactericidal effects against E. coli at concentrations of 50-100 mg/mL. No human clinical trials have been conducted to validate these effects or establish safe dosing parameters. The presence of hepatotoxic pyrrolizidine alkaloids has led to restricted use in many countries despite traditional applications for respiratory conditions.
Coltsfoot contains pyrrolizidine alkaloids that can cause serious liver damage, including hepatic veno-occlusive disease and liver cirrhosis with chronic use. The herb is contraindicated during pregnancy and breastfeeding due to potential teratogenic effects and alkaloid transfer to breast milk. Coltsfoot may interact with hepatotoxic medications and should be avoided by individuals with existing liver disease. Many countries have banned or restricted coltsfoot-containing products due to safety concerns, with some requiring pyrrolizidine alkaloid-free preparations.
